This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Vifor Pharma Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

42.3%

Tasso di crescita degli utili

41.4%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	24.1%
Tasso di crescita dei ricavi	8.5%
Rendimento futuro del capitale proprio	13.4%
Copertura analitica	Low
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

OTCPK:GNHA.F - Stime future degli analisti e dati finanziari passati (CHF Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2024	2,353	N/A	N/A	N/A	1
12/31/2023	2,159	356	734	682	2
12/31/2022	1,980	307	683	622	2
12/31/2021	1,812	147	414	527	N/A
6/30/2021	1,753	213	169	441	N/A
3/31/2021	1,757	176	119	432	N/A
12/31/2020	1,762	139	70	424	N/A
6/30/2020	1,709	93	301	500	N/A
3/31/2020	1,732	101	350	512	N/A
12/31/2019	1,754	108	399	525	N/A
9/30/2019	1,845	129	280	439	N/A
6/30/2019	1,784	100	169	353	N/A
3/31/2019	1,711	126	44	274	N/A
12/31/2018	1,639	152	-82	194	N/A
9/30/2018	1,571	157	-110	132	N/A
6/30/2018	1,504	162	-139	70	N/A
3/31/2018	1,441	98	-83	65	N/A
12/31/2017	1,378	34	-28	60	N/A
9/30/2017	1,345	26	-15	90	N/A
6/30/2017	1,312	18	-2	120	N/A
3/31/2017	1,283	82	4	190	N/A
12/31/2016	1,254	147	10	259	N/A
9/30/2016	1,944	218	139	418	N/A
6/30/2016	2,635	290	267	577	N/A
3/31/2016	3,265	295	312	550	N/A
12/31/2015	3,896	301	358	522	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: GNHA.F's forecast earnings growth (42.3% per year) is above the savings rate (2%).

Guadagni vs Mercato: GNHA.F's earnings (42.3% per year) are forecast to grow faster than the US market (13.5% per year).

Guadagni ad alta crescita: GNHA.F's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: GNHA.F's revenue (8.5% per year) is forecast to grow faster than the US market (7.3% per year).

Ricavi ad alta crescita: GNHA.F's revenue (8.5% per year) is forecast to grow slower than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: GNHA.F's Return on Equity is forecast to be low in 3 years time (13.4%).

This company has been acquired

Vifor Pharma Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Recent updates

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial

Vifor Pharma AG(SWX:VIFN) dropped from Swiss Performance Index (Price Return)

CSL Plans to Pursue an Application to SIX Exchange Regulation for the Delisting of the Vifor Pharma Shares

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®

Vifor Pharma and American Regent Announce Settlement Agreements with Mylan Laboratories Ltd., and Sandoz, Inc., of Injectafer Patent Litigation

Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing Business of Vifor Pharma Group.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Pharma AG Announces Enrolmenet of First Patient in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Vifor Says Regularly in Talks with Other Market Participants After Reports

Vifor Pharma AG (SWX:VIFN) entered into a definitive agreement to acquire Sanifit Therapeutics S.A. from group of investor for €375 million.

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Vifor Pharma to Revise DIAMOND Study

Vifor Pharma AG Approves Dividend, Payable from 12 May 2021

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Vifor Pharma AG Provides Phase-II Clinical Trial of VIT-2763 in Non-Transfusion-Dependent Beta-Thalassemia Is Expected to Be Completed in the Second Half of 2021

Vifor Pharma Announces Board Changes

Vifor Pharma Presents the Full Results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Optimus Holding Ltd. completed the acquisition of OM Pharma SA from Vifor Pharma AG (SWX:VIFN).

Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita